EU regulators have published a much-awaited recommendation paper offering their harmonized perspective on the use of decentralized elements in clinical trials undertaken in the EU/European Economic Area.
The recommendation paper, published on 14 December, is a joint initiative of the European Medicines Agency, the European Commission and the EU Heads of Medicines Agencies (HMA)